Adicet Appoints Don Healey, Ph.D., as Chief Technology Officer
October 26 2020 - 3:10PM
Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company
discovering and developing first-in-class allogeneic gamma delta T
cell therapies for cancer and other diseases, today announced the
appointment of Don Healey, Ph.D., as Chief Technology Officer. Dr.
Healey will lead the development of Adicet’s genetically-modified T
cell therapies for clinical development and commercialization,
including manufacturing, viral vector operations and analytics.
“We are excited to welcome Don as a new member of Adicet’s
Executive Leadership Team,” said Chen Schor, President and Chief
Executive Officer of Adicet. “Don’s expertise in guiding the
production and release of cell therapy products, as well as his
deep knowledge of the scientific, technical, and strategic
approaches to genetically modifying, characterizing and scaling the
production of such cell products is a valuable addition to the
growth of Adicet as we continue to advance our pipeline of
'off-the-shelf' gamma delta T cell product candidates.”
“I am honored to join the Adicet team, and look forward to
helping guide the development of ADI-001 through the next stages of
development and registration,” said Dr. Healey. “I am very excited
by the potential of Adicet’s gamma delta T cell platform and its
novel targeting approaches. Adicet’s platforms and product
candidates are highly differentiated and may provide oncology
patients with selective tumor targeting, innate and adaptive
anti-tumor immune response, and improved persistence for durable
activity.”
Dr. Healey has nearly two decades of experience in cell therapy
development and manufacturing. Dr. Healey joins Adicet most
recently from KBI Biopharma Inc., a biopharmaceutical contract
services organization, where he was responsible for establishing
process development, manufacturing, quality control and facilities
management for biopharmaceutical clients developing cellular
therapies. Previously, he served as Chief Scientific Officer at
Opexa Therapeutics, Inc., where he was responsible for all
pre-clinical scientific development, closed-system process design
and the scaling of Opexa's autologous T-cell immunotherapy. Dr.
Healey has also served as Director of Immunology at Argos
Therapeutics Inc. and Group leader for Immunology at ML
Laboratories, UK, (formerly Cobra Biotherapeutics). Dr. Healey
received his Ph.D. from University of London, and holds a B.Sc. in
Cellular Pathology from Bristol University.
About Adicet
Adicet is a biotechnology company discovering and developing
allogeneic gamma delta T cell therapies for cancer and other
diseases. Adicet is advancing a pipeline of “off-the-shelf” gamma
delta T cells, engineered with chimeric antigen receptors and T
cell receptor-like antibodies to enhance selective tumor targeting,
facilitate innate and adaptive anti-tumor immune response, and
improve persistence for durable activity in patients. For
more information, please visit our website
at http://www.adicetbio.com.
Forward-Looking StatementsThis press release
contains "forward-looking statements" of Adicet within the meaning
of the Private Securities Litigation Reform Act of 1995 relating to
business and operations of Adicet including, but not limited to,
preclinical and clinical development of Adicet’s product
candidates, including future plans or expectations for ADI-001 and
potential therapeutic effects of ADI-001. Any forward-looking
statements in this press release are based on management’s current
expectations and beliefs of future events, and are subject to a
number of risks and uncertainties that could cause actual results
to differ materially and adversely from those set forth in or
implied by such forward-looking statements, including without
limitation, the effect of COVID-19 on Adicet’s business and
financial results, including with respect to disruptions to our
clinical trials, business operations, employee hiring and
retention, and ability to raise additional capital; Adicet’s
ability to execute on its strategy; Adicet’s ability to meet
production and product release expectations; as well as those risks
and uncertainties set forth in the company’s most recent annual
report on Form 10-K and subsequent filings with the Securities
and Exchange Commission. For a discussion of these and
other risks and uncertainties, and other important factors, any of
which could cause Adicet’s actual results to differ from those
contained in the forward-looking statements, see the section
entitled “Risk Factors” in Adicet’s most recent annual report on
Form 10-K and our periodic reports on Form 10-Q and Form 8-K filed
with the SEC, as well as discussions of potential risks,
uncertainties, and other important factors in Adicet’s other
filings with the SEC. All information in this press release is
as of the date of the release, and Adicet undertakes no duty
to update this information unless required by law.
Investor and Media
ContactsAnne
Bowdidgeabowdidge@adicetbio.com
Janhavi MohiteStern Investor Relations,
Inc.212-362-1200janhavi.mohite@sternir.com
Adicet Bio (NASDAQ:ACET)
Historical Stock Chart
From Apr 2024 to May 2024
Adicet Bio (NASDAQ:ACET)
Historical Stock Chart
From May 2023 to May 2024